Search
Close this search box.
    • Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Financial results

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Annual Report 2023: Exceptional partnerships, dynamic growth

Watch this video to catch a glimpse of the incredible milestones we have achieved over the past year. Explore how we are shaping the future of science and medicine with our collaborative partnerships based on the foundation of common interest, shared commitment, complementary skills, and desire to work together. To know more about the innovative solutions and transformative projects we delivered in FY2022-23, read our Annual Report

MD & CEO Jonathan Hunt’s year-end reflections and outlook for FY24

Watch this video where our MD and CEO, Jonathan Hunt, shares his perspective on the financial year gone by, and the outlook for FY24. Syngene’s sustained positive performance in the fourth quarter delivered strong full-year results. Revenue from operations in Q4 grew by 31%, while full-year revenue from operations in FY 23 grew by 23%. To read the press release, click here.

CFO Sibaji Biswas' year-end reflections and outlook for FY24

Watch this video where our CFO, Sibaji Biswas, shares his perspective on a trend-breaking year with revenue growth of 23% year-on-year. Syngene delivered the highest absolute year-on-year increase in revenue and EBITDA compared to the last five years. While the research business and Dedicated Centers delivered a strong performance, Development and Manufacturing services grew by 28% year-on-year. To read the full press release, click here.

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details